Reported Earlier, Genmab's Epcoritamab Shows 95% Response Rate In Untreated Follicular Lymphoma Patients In Preliminary EPCORE NHL-2 Study Results
Portfolio Pulse from Benzinga Newsdesk
Genmab's Epcoritamab shows a 95% response rate in untreated follicular lymphoma patients in preliminary EPCORE NHL-2 study results. The EPCORE NHL-1 study also shows a reduction in cytokine release syndrome and neurotoxicity in relapsed/refractory patients.
June 03, 2024 | 6:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genmab's Epcoritamab demonstrates a 95% response rate in untreated follicular lymphoma patients, indicating strong efficacy. Additionally, reduced side effects in relapsed/refractory patients could enhance the drug's market potential.
The high response rate in untreated patients and reduced side effects in relapsed/refractory patients suggest strong efficacy and safety profile for Epcoritamab. This could lead to increased investor confidence and potential stock price appreciation for Genmab.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100